Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, Mazzoni E, Bonaventura ME, Nosotti L, Arcuri P, Picardi A, Barbarini G, D'Ambrosio C, Paffetti A, Andreoli A, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.
Mecenate F, et al. Among authors: barbaro g.
BMC Gastroenterol. 2010 Feb 19;10:21. doi: 10.1186/1471-230X-10-21.
BMC Gastroenterol. 2010.
PMID: 20170514
Free PMC article.
Clinical Trial.